Here are four points:
1. Wright Medical can now initiate commercial sale and distribution of the bone graft in the United States.
2. The bone graft is intended as an alternative to autograft for ankle and/or hindfoot fusion indications.
3. The bone graft features a combination of two components — recombinant human Platelet-Derived Growth Factor and Beta-tricalcium phosphate.
4. The bone graft has undergone clinical trial and testing, and the FDA’s PMA application approval indicates that the FDA has determined that the graft is safe and effective.
More articles on devices:
Integra LifeSciences acquires Tornier foot & ankle products ahead of Wright Medical merger: 5 key notes
4 notes about Genesys Spine ranking on Inc. 5000 List for 2nd year
Medtronic Q1 revenue soars 12%, Core Spine flat: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
